多替阿巴拉米片服用量是多少呢？

It cannot be used for individuals who carry the HLA-B*5701 gene. Patients who carry this gene will have a high risk of severe hypersensitivity reactions (type I allergic reactions) when using dolutea palamid tablets. Therefore, it is necessary to complete the test before taking Dolutea Paramid Tablets to determine whether you carry the special type of "HLA-B*5701" gene. However, most hospitals cannot do this test now. Generally, doctors will communicate the risk with the patient first. Today we are going to find out what is the dosage of Dota Abalami Tablets?

On January 22, 2018, GlaxoSmithKline (GSK) announced that its joint venture ViiV Healthcare’s single-tablet compound preparation dolutegravir (chemical name: dolutegravir) as the core for the treatment of HIV, a single-tablet compound preparation dolutegravir, was officially launched in mainland China. The drug is the only three-in-one compound drug containing dolutegravir. It is taken once a day and has one tablet at a time. It has the characteristics of high efficiency, good tolerance, high resistance barrier and few drug interactions.

Dosage: For adults and adolescents (with a body weight of at least 40kg), the recommended dose of Dolutegra is one tablet, once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. 

Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

  Missed dose If the patient misses a dose of Docetaxel, and it is more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. 

The above is the dosage content, I hope it can help you!